Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.19

-4.7%

Jan 15 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (15117)	1/6/2005 2:58:47 PM
From: Rudy Saucillo	Read Replies (1) of 52153

Curious that these studies didn't address the correlation of other known inflammation markers with CV events. "Acute Coronary Syndrome and Inflammation. Biomarkers for Diagnostics and Risk Stratification." ncbi.nlm.nih.gov For example, myeloperoxidase (mentioned in the above abstract) was reduced by statistically significant amounts in the AGIX CART II treatment group. Corresponding plaque reduction in the treatment group was statistically significant w.r.t. baseline and w.r.t. SOC in the 10mm most diseased segments. One reason CRP is studied extensively appears to be ease of measurement: "CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper." ncbi.nlm.nih.gov Interestingly, myeloperoxidase is also associated with kidney disease: "Myeloperoxidase in kidney disease" ncbi.nlm.nih.gov "Are advanced oxidation protein products potential uremic toxins?" ncbi.nlm.nih.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next